Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illumina, Inc. (ILMN) vs TORM plc (TRMD) Price & Performance

Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs TORM plc — how do they compare? Illumina, Inc. trades at $266.99 (market cap $39.95B), while TORM plc trades at $39.91 (market cap $4.12B). The key difference: Illumina, Inc. is far larger — about 9.7× TORM plc's market cap, and TORM plc pays a 11.03% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and TORM plc for 23 Days on average.

ILMNTRMD
Market Cap
$39.95B$4.12B
Volume
3,169,5032,863,116
Sector
HealthIndustrials
52-Week High
$293.69$41.05
52-Week Low
$91.00$19.39
Typical Hold Time
83 Days23 Days
Enterprise Value
$41.31B$4.83B
Dividend Yield
—11.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.

The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.

TORM plc

TRMD trades at $38.92, down 0.33% on the day, with strong profitability metrics including 35.52% net income margin and 26.84% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent earnings showed mixed results with Q2 2026 missing expectations, while analyst consensus remains unanimously bullish with 100% buy ratings. The company maintains robust cash flow generation with $710M operating cash flow projected for 2026.

TRMD presents attractive valuation with P/E of 6.4 and EV/EBITDA of 5.11, supported by strong dividend yield from upcoming $2.40 payment. Key risks include spot rate volatility in tanker markets and recent insider selling activity. The fundamental outlook remains positive given projected revenue growth to $1.8B in 2026, though investors should monitor freight rate trends and competitive pressures in the product tanker sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ILMN
96% Buy4% Sell
Avg holding period · 83 Days
TRMD
23% Buy77% Sell
Avg holding period · 23 Days

Top news

Latest headlines on both assets

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN →

About TORM plc

TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.

Read more on TRMD →